Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that.
Coastwise Capital Group LLC trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,104 shares of the biopharmaceutical company’s stock after selling 6,668 shares during the quarter. Coastwise Capital Group LLC’s holdings […]
Redwood Investment Management LLC lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 1,464.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 135,558 shares of the biopharmaceutical company’s stock after purchasing an additional 126,893 shares during the […]
OLD Point Trust & Financial Services N A bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,531 shares of the biopharmaceutical company’s stock, valued at approximately $284,000. […]
Elo Mutual Pension Insurance Co lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,392 shares of the biopharmaceutical company’s stock after purchasing an additional 6,559 shares during […]